| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration |
|
Medicine details |
|
| Medicine name | aflibercept (Eylea®) |
| Formulation | 40 mg/ml solution for injection |
| Reference number | 466 |
| Indication | Treatment of neovascular (wet) age-related macular degeneration in adults |
| Company | Bayer Healthcare Pharmaceuticals |
| BNF chapter | Eye |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 29/11/2012 |
| NICE guidance | TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration |